IOLAB’s LIVOSTIN OPHTHALMIC SUSPENSION APPROVED NOV. 10
Executive Summary
IOLAB's LIVOSTIN OPHTHALMIC SUSPENSION APPROVED NOV. 10 for "temporary relief of the signs and symptoms of seasonal allergic conjunctivitis" (SAC), labeling states. Livostin (levocabastine, under development by the Johnson & Johnson unit as Levocon) was classified "1P" by FDA, designating a new molecular entity that received priority review from the agency. FDA's approval letter notes that the NDA (20-219) was filed on Sept. 20, 1991 and the last amendment to the NDA was received Nov. 10. Livostin is a selective histamine H[1],- receptor antagonist for ophthalmic uses, labeling states. Labeling notes that "antigen challenge studies performed two to four hours after initial drug instillation showed that activity was maintained for at least two hours." Livostin will join two other Iolab prescription products on the market that are indicated for SAC: Inflamase (prednisolone sodium phosphate) and the combination product Vasocon-A (antazoline phosphate/naphazoline). Other ophthalmic products designated for SAC include antihistamine/decongestant combinations, nonsteroidal anti-inflammatory drugs and steroids. For treatment of SAC, Livostin's usual dose is "one drop instilled in affected eyes four times a day" for up to two weeks. Mild, transient stinging and burning occurred in 15% of patients and 5% experienced headaches, approved labeling states. Visual disturbances, dry mouth, fatigue, pharyngitis, eye pain and dryness, somnolence, red eyes, cough, nausea, rash, eyelid edema and dyspnea was reported in 3% or less of Livostin users. Livostin is not recommended for use while contact lenses are being worn. The agency approval letter notes Iolab's commitment in an Oct. 13 NDA amendment "to correct bottle and carton labels when the current supply of 100,000 is exhausted or at the next printing." Additionally, FDA requests that Claremont, Calif.-based Iolab "provide the thermo-gravimetric and X-ray powder diffraction analyses of the drug substance made under the old and the new processes." Livostin is supplied in 2.5 ml, 5 ml and 10 ml polyethylene dropper tip squeeze bottles. Iolab, which plans to launch Livostin in the "near future," says it has not yet established the product's price.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth